In contrast to the above-cited studies involving PITX2 DNA methylation status in ER/PR+ breast cancer patients, the results obtained by Absmaier et al. revealed evidence that for TNBC patients treated with adjuvant anthracycline-based chemotherapy, a low PITX2 DNA methylation status is associated with a decrease in the progression-free interval [66]. The gene discussed is PGR; the disease is breast cancer.